SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 28, 2016
Intermolecular, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
001-35348 |
20-1616267 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
3011 N. First Street San Jose, California |
95134 |
|
|
(Address of Principal Executive Offices) |
(Zip Code) |
|
(408) 582-5700 |
|
(Registrant's Telephone Number, Including Area Code) |
|
N/A |
|
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
◻Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
◻Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a‑12)
◻Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
◻Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01 REGULATION FD DISCLOSURE
Incorporated by reference is a press release issued by Intermolecular, Inc. on March 28, 2016, which is attached hereto as Exhibit 99.1. This information is being furnished under Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
|
|
|
|
|
|
|
Exhibit |
|
Description |
|
|
|
|
|
|
|
99.1 |
|
Press Release issued by Intermolecular, Inc. on March 28, 2016 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INTERMOLECULAR, INC. |
||
|
Date: March 28, 2016 |
By: |
/s/ Scot A. Griffin |
|
Scot A. Griffin |
||
|
Executive Vice President and Corporate Secretary |
||
Intermolecular Files Fiscal Year 2015 Financial Statements
SAN JOSE, Calif., March 28, 2016 -- Intermolecular, Inc. (NASDAQ: IMI) today filed its annual report on Form 10-K for the full year ended December 31, 2015.
The Company’s Form 10-K reports fourth quarter and annual revenues of $13.0 million and $45.3 million, respectively, instead of the previously reported quarterly and annual revenues of $13.5 million and $45.8 million, respectively.
Subsequent to the Company’s earnings call on February 4, 2016, management determined that $500,000 of revenue from a certain customer that was recognized in the fourth quarter ended December 31, 2015 should have been recognized as revenue in the first quarter that will end on March 31, 2016. The Company expects to recognize the $500,000 of revenue in the first quarter that will end on March 31, 2016.
About Intermolecular, Inc.
Intermolecular® is the trusted partner for advanced materials innovation. Advanced materials are at the core of innovation in the 21st century for a wide range of industries including semiconductors, consumer electronics, automotive and aerospace. With its substantial materials expertise; accelerated learning and experimentation platform; and information and analytics infrastructure, Intermolecular has a ten-year track record helping leading companies accelerate and de-risk materials innovation.
“Intermolecular” and the Intermolecular logo are registered trademarks; all rights reserved. Learn more at www.intermolecular.com.
Forward-Looking Statements
Statements made in this press release and the earnings call referencing the press release that are not statements of historical fact are forward-looking statements. Forward-looking statements are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to, but are not limited to, our ability to productize our workflows with existing and future customers; expectations regarding our first quarter 2016 and future revenue, cash flow and GAAP and non-GAAP net income or loss; the ability of our new business model to generate long-term shareholder returns; the extent to which technology developed in collaboration with our customers will continue to remain on the critical path and have significant value for such customers and us as well as the industry as a whole; and anticipated growth in our current markets through expansion of existing customer programs and the entry into other engagements with new customers. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to: our ability to execute on our strategy, prove our business model and remain technologically competitive in rapidly evolving industry conditions; commercial acceptance of our HPC platform and methodology as effective R&D tools; our ability to achieve and sustain profitability; the ability of our customers to achieve their announced product roadmaps in a timely manner; the extent to which we are able to successfully extend and expand relationships with existing customers; our ability to manage the growth of our business; the rapid technology changes and volatility of the customers and industries we serve; our potential need for future capital to finance our operations; and other risks described in our most recent Annual Report on
Form 10-K as filed with the SEC and available at www.sec.gov, particularly in the section titled "Risk Factors." All forward-looking statements are based on management’s current estimates, projections and assumptions, and we assume no obligation to update them.
CONTACT:
Rick Neely
Intermolecular, Inc.
Sr. Vice President and Chief Financial Officer
rick.neely@intermolecular.com
+1.408.582.5430